Astellas and Celgene-backed immuno-oncology therapy developer Oncorus has filed to raise up to $86.3m following more than $150m in funding.

US-based cancer immunotherapy developer Oncorus has filed for an $86.3m initial public offering that would allow pharmaceutical firms Astellas and Celgene to exit. Oncorus is working on viral immunotherapies to treat cancer, and its lead product candidate, ONCR-177, utilises Herpes Simplex Virus (HSV) type 1 to stimulate the immune system to fight and destroy tumours.…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.